Lyell Immunopharma is a clinical-stage company advancing next-generation CAR T-cell product candidates for patients with cancer, focusing on delivering lasting remissions and potential cures through innovative cell therapy
Lyell Immunopharma is a clinical-stage company advancing next-generation CAR T-cell product candidates for patients with cancer, focusing on delivering lasting remissions and potential cures through innovative cell therapy.